{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:06:22Z","timestamp":1789693582026,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.07.023","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:29:14Z","timestamp":1787264954000},"page":"173-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination\u2013deficient stage III\/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial"],"prefix":"10.1016","volume":"212","author":[{"given":"Shannon N.","family":"Westin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Belotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunella","family":"Felicetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvajit","family":"Aghera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"YoussefAgha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Bakirtzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Godoy","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantzazu Barqu\u00edn","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal M\u00e1rquez","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Gonz\u00e1lez","family":"Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda B.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rojas-Espaillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2026.07.023_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.07.023_bb0010","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.023_bb0015","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.07.023_bb0020","series-title":"Survival for Ovarian cancer","author":"Cancer Research UK","year":"2025"},{"issue":"28","key":"10.1016\/j.ygyno.2026.07.023_bb0025","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.07.023_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9990","key":"10.1016\/j.ygyno.2026.07.023_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.ygyno.2026.07.023_bb0040","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","volume":"7","author":"Coleridge","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.023_bb0045","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer","volume":"2","author":"Shawky","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.ygyno.2026.07.023_bb0050","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.023_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2022.08.005","article-title":"Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: a retrospective study from the ESME national cohort","volume":"167","author":"Thomas","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"25","key":"10.1016\/j.ygyno.2026.07.023_bb0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian Cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.023_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08142-5","volume":"25","author":"Belotte","year":"2024","journal-title":"Trials"},{"issue":"18","key":"10.1016\/j.ygyno.2026.07.023_bb0070","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2026.07.023_bb0075","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1200\/JCO.2024.42.16_suppl.5549","article-title":"Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: a prospective, multicenter, phase II, single-arm NANT study","volume":"42","author":"Gao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.023_bb0080","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2023.06.467","article-title":"Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)","volume":"176","author":"Westin","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.023_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.023_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114157","article-title":"Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy","volume":"208","author":"Vulsteke","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2026.07.023_bb0095","doi-asserted-by":"crossref","first-page":"e17555","DOI":"10.1200\/JCO.2024.42.16_suppl.e17555","article-title":"Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: a single-arm, prospective phase II trial","volume":"42","author":"Liu","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:34Z","timestamp":1789692094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S0090825826020895"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination\u2013deficient stage III\/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}